Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27468266 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5458819 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5437211 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5437853 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5437270 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5436202 | 1.00 | CYP1A2 (0.39) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL19052736 | 0.75 | CYP1A2 (0.36) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5432984 | 0.74 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7772830 | 0.74 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14459044 | 0.74 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885ALDH1A1 268/4885USP2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.